Vivani Medical Inc. Common Stock (DE) (VANI)
VANI trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1266806/000175392626000548/0001753926-26-000548-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | VANI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001266806 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$26.6M |
| Operating income | -$27.6M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $16.2M |
| Total assets | $39.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued." | 10-Q 2026-11-12 |
| Cash and burn | $14.6M cash; operating cash flow -$6.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 90,203,356 (2026-11-12); 72,952,235 a year earlier; 51,025,060 three years earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-09-25 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BPM LLP, Walnut Creek, California, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $26.6M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$7.3M | -$6.4M | $14.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$6.4M | -$6.0M | $19.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$6.8M | -$6.2M | $19.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$6.6M | -$6.7M | $16.2M | No debt tags | $0 | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | Not filed | -$6.5M | -$6.4M | $2.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $0 | -$7.1M | -$6.1M | $6.8M | No debt tags | $0 | 10-Q 2025-08-13 |
| Q1 2025 2025-03-31 | $0 | -$6.3M | -$5.2M | $13.0M | No debt tags | Needs four quarters | 10-Q 2025-05-13 |
| Q4 2024 2024-12-31 | $0 | -$6.0M | -$5.8M | $18.4M | No debt tags | $0 | 10-K 2025-03-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-25 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy DEFA 14A | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 843 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.6% |
| 1 month | -14.4% |
| 3 months | -24.6% |
| Year to date | -17.9% |
| 1 year | -25.5% |
| From 52-week high | -36.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HSDT | Solana Company Class A Common Stock (DE) | $1.64 | -5.20% | $103.1M |
| STXS | Stereotaxis Inc. | $0.8027 | -4.80% | $80.4M |
| NRXS | Neuraxis Inc. | $4.80 | -11.44% | $68.1M |
| HYPR | Hyperfine Inc. | $0.6101 | -3.05% | $64.8M |
| OM | Outset Medical Inc. | $3.39 | -9.12% | $64.0M |
| FOCL | EDAP TMS S.A. | $3.17 | -2.39% | $149.7M |
| POCI | Precision Optics Corporation Inc. | $4.97 | -4.97% | $54.6M |
| ELMD | Electromed Inc. | $23.10 | -5.02% | $188.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier